HCA Healthcare, Inc. $HCA Position Increased by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd boosted its stake in HCA Healthcare, Inc. (NYSE:HCA) by 48.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,151 shares of the company’s stock after buying an additional 2,329 shares during the period. Mediolanum International Funds Ltd’s holdings in HCA Healthcare were worth $3,010,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of HCA. Lebenthal Global Advisors LLC boosted its stake in HCA Healthcare by 177.2% during the 3rd quarter. Lebenthal Global Advisors LLC now owns 1,716 shares of the company’s stock valued at $732,000 after purchasing an additional 1,097 shares during the period. Fortem Financial Group LLC boosted its position in shares of HCA Healthcare by 7.4% during the third quarter. Fortem Financial Group LLC now owns 5,400 shares of the company’s stock worth $2,301,000 after buying an additional 370 shares during the period. UMB Bank n.a. raised its stake in HCA Healthcare by 4.7% during the 3rd quarter. UMB Bank n.a. now owns 1,726 shares of the company’s stock valued at $736,000 after acquiring an additional 78 shares in the last quarter. Transcend Capital Advisors LLC grew its stake in shares of HCA Healthcare by 47.2% in the third quarter. Transcend Capital Advisors LLC now owns 1,519 shares of the company’s stock worth $647,000 after purchasing an additional 487 shares in the last quarter. Finally, Lee Financial Co lifted its holdings in HCA Healthcare by 4.1% in the third quarter. Lee Financial Co now owns 816 shares of the company’s stock worth $348,000 after purchasing an additional 32 shares during the period. 62.73% of the stock is currently owned by institutional investors.

HCA Healthcare Price Performance

Shares of HCA opened at $496.30 on Tuesday. HCA Healthcare, Inc. has a one year low of $295.00 and a one year high of $527.55. The company has a 50-day moving average of $480.98 and a two-hundred day moving average of $439.27. The stock has a market cap of $113.25 billion, a price-to-earnings ratio of 17.49, a PEG ratio of 1.50 and a beta of 1.36.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, beating the consensus estimate of $7.37 by $0.64. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The business had revenue of $19.51 billion during the quarter, compared to the consensus estimate of $19.67 billion. During the same quarter in the prior year, the firm earned $6.22 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be given a dividend of $0.78 per share. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, March 17th. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. HCA Healthcare’s dividend payout ratio is 10.15%.

Insider Buying and Selling

In other HCA Healthcare news, EVP Michael R. Mcalevey sold 3,892 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total value of $1,843,990.68. Following the transaction, the executive vice president owned 3,487 shares in the company, valued at approximately $1,652,105.73. This represents a 52.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of HCA Healthcare from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. Cantor Fitzgerald increased their price target on HCA Healthcare from $525.00 to $588.00 and gave the company an “overweight” rating in a research note on Wednesday, January 28th. The Goldman Sachs Group upped their price objective on HCA Healthcare from $520.00 to $558.00 and gave the company a “buy” rating in a report on Wednesday, January 28th. Leerink Partners boosted their price target on shares of HCA Healthcare from $507.00 to $573.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 28th. Finally, Mizuho set a $540.00 price objective on shares of HCA Healthcare in a research note on Monday. Fifteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $519.71.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.